Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.39 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833770 | 0.93 | PTPN2 (0.40) | IMPDH2ALBMAP1LC3BMAP1LC3AHIF1A | |
| SCHEMBL6834401 | 0.88 | GPR27 (0.46) | IMPDH2ALBHIF1APTPN2PTPN1 | |
| SCHEMBL6833193 | 0.87 | ALB (0.42) | ALBHIF1AMCL1 | |
| SCHEMBL6817851 | 0.86 | IMPDH2 (0.41) | IMPDH2ALBMAP1LC3BMAP1LC3APTPN2 | |
| SCHEMBL6835761 | 0.85 | ALB (0.39) | ALBHIF1ACCR2CDK2 | |
| SCHEMBL6815109 | 0.85 | ALB (0.40) | IMPDH2ALBPTPN2PTPN1PTPN5 | |
| SCHEMBL6708554 | 0.84 | MAP1LC3B (0.37) | IMPDH2MAP1LC3BMAP1LC3AHIF1APTPN2 | |
| SCHEMBL6711824 | 0.84 | IMPDH2 (0.37) | IMPDH2MAP1LC3BMAP1LC3AHIF1APTPN2 | |
| SCHEMBL6818576 | 0.82 | GPR27 (0.46) | ALBPTPN2PTPN1PTPN5CCR2 | |
| SCHEMBL6830330 | 0.82 | SLC16A3 (0.44) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | IMPDH2 2762/4885ALB 1417/4885MAP1LC3B 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.